LSE - Delayed Quote GBp

MaxCyte, Inc. (MXCT.L)

394.00

+11.00

+(2.87%)

At close: January 17 at 5:15:01 PM GMT

All You Need to Know About MaxCyte (MXCT) Rating Upgrade to Strong Buy

MaxCyte (MXCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 3 days ago

MXCT
+4.00%
What Is MaxCyte, Inc.'s (LON:MXCT) Share Price Doing?

While MaxCyte, Inc. ( LON:MXCT ) might not have the largest market cap around , it saw a significant share price rise...

Simply Wall St. 3 days ago

MXCT
+4.00%
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

ROCKVILLE, Md., Jan. 13, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today provided a preliminary update on financial results for the fourth quarter and full year ended December 31, 2024. Preliminary Unaudited Fourth Quarter and Full Year 2024 Results Core revenue in the fourth quarter is expe

GlobeNewswire 5 days ago

MXCT
+4.00%
MaxCyte, Inc.'s (LON:MXCT) Intrinsic Value Is Potentially 72% Above Its Share Price

Key Insights MaxCyte's estimated fair value is UK£5.59 based on 2 Stage Free Cash Flow to Equity MaxCyte's UK£3.24...

Simply Wall St. 17 days ago

MXCT
+4.00%
MaxCyte Announces Retirement of Board Member Art Mandell

ROCKVILLE, Md., Dec. 22, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that Art Mandell has retired from his position as a member of the Board of Directors of MaxCyte effective December 31, 2024. Mr. Mandell has served on the Board since 2006 and has been an integral part of MaxC

GlobeNewswire 26 days ago

MXCT
+4.00%
MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance

ROCKVILLE, Md., Dec. 08, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the completion of an internal operational review, initiated earlier this year following the appointment of Maher Masoud as President and Chief Executive Officer. This “bottom-up” review focused on optimizing ne

GlobeNewswire last month

MXCT
+4.00%
This MaxCyte Insider Increased Their Holding In The Last Year

Looking at MaxCyte, Inc.'s ( LON:MXCT ) insider transactions over the last year, we can see that insiders were net...

Simply Wall St. last month

MXCT
+4.00%
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics

Since 1999, MaxCyte’s non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projectsROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, marks the 25th anniversary of its founding this year. Over the past quarter-century, the company has rem

GlobeNewswire 2 months ago

MXCT
+4.00%
MaxCyte Inc (MXCT) Q3 2024 Earnings Call Highlights: Strong Core Revenue Growth Amidst Market ...

MaxCyte Inc (MXCT) reports a 23% increase in core revenue and maintains a robust cash position, despite a decline in gross margin and drug discovery revenue.

GuruFocus.com 2 months ago

MXCT
+4.00%
MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates

MaxCyte (MXCT) delivered earnings and revenue surprises of 15.38% and 8.85%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

MXCT
+4.00%
MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance

ROCKVILLE, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics, today announced its financial results for the third quarter ended September 30, 2024, and updated its 2024 guidance. Third Quarter and Recent Highlights Total revenue of $8.2 million in the third quarter of 2024, an increase

GlobeNewswire 2 months ago

MXCT
+4.00%
MaxCyte to Participate in Two Upcoming Investor Conferences

ROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced Company management will participate at two upcoming investor conferences. Stifel 2024 Healthcare ConferenceFireside Chat on Monday, November 18th at 10:55 AM ET Stephens Annual Investment ConferenceFires

GlobeNewswire 2 months ago

MXCT
+4.00%
MaxCyte, Inc. (LON:MXCT) is largely controlled by institutional shareholders who own 65% of the company

Key Insights Significantly high institutional ownership implies MaxCyte's stock price is sensitive to their trading...

Simply Wall St. 2 months ago

MXCT
+4.00%
MaxCyte (MXCT) Upgraded to Strong Buy: What Does It Mean for the Stock?

MaxCyte (MXCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks 3 months ago

MXCT
+4.00%
MaxCyte Appoints Cynthia Collins to its Board of Directors

ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Cynthia Collins to the Company’s Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board’s

GlobeNewswire 3 months ago

CERT

DMTKQ

MXCT
+4.00%
MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024

ROCKVILLE, Md., Oct. 11, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced that it will release financial results for the third quarter 2024 after the U.S. market close on Wednesday, November 6th, 2024. Company management will host a conferen

GlobeNewswire 3 months ago

MXCT
+4.00%
MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer

ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Ali Soleymannezhad as Chief Commercial Officer, effective as of September 11, 2024. In his new role, Mr. Soleymannezhad will lead MaxCyte’s co

GlobeNewswire 3 months ago

MXCT
+4.00%
MaxCyte Inc (MXCT) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Core Challenges

MaxCyte Inc (MXCT) reports a 15% revenue increase, driven by SPL Program success, despite declines in core and cell therapy revenues.

GuruFocus.com 3 months ago

MXCT
+4.00%
We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 3 months ago

MXCT
+4.00%
MaxCyte and Kamau Therapeutics sign platform license agreement

Kamau Therapeutics will gain non-exclusive research, clinical and commercial rights to utilise MaxCyte's Flow Electroporation technology and ExPERT platform.

Pharmaceutical Technology 3 months ago

MXCT
+4.00%

Performance Overview

Return	MXCT.L	FTSE 100
YTD	+25.48%	+4.73%
1-Year	-6.19%	+12.53%
3-Year	-30.88%	+12.76%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

MaxCyte, Inc. (MXCT.L)

All You Need to Know About MaxCyte (MXCT) Rating Upgrade to Strong Buy

What Is MaxCyte, Inc.'s (LON:MXCT) Share Price Doing?

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

MaxCyte, Inc.'s (LON:MXCT) Intrinsic Value Is Potentially 72% Above Its Share Price

MaxCyte Announces Retirement of Board Member Art Mandell

MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance

This MaxCyte Insider Increased Their Holding In The Last Year

MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics

MaxCyte Inc (MXCT) Q3 2024 Earnings Call Highlights: Strong Core Revenue Growth Amidst Market ...

MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates

MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance

MaxCyte to Participate in Two Upcoming Investor Conferences

MaxCyte, Inc. (LON:MXCT) is largely controlled by institutional shareholders who own 65% of the company

MaxCyte (MXCT) Upgraded to Strong Buy: What Does It Mean for the Stock?

MaxCyte Appoints Cynthia Collins to its Board of Directors

MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024

MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer

MaxCyte Inc (MXCT) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Core Challenges

We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth

MaxCyte and Kamau Therapeutics sign platform license agreement

Performance Overview